Buch, Englisch, 384 Seiten, Format (B × H): 152 mm x 229 mm
Buch, Englisch, 384 Seiten, Format (B × H): 152 mm x 229 mm
ISBN: 978-0-12-369370-9
Verlag: Academic Press
Zielgruppe
Advanced undergraduate and graduate students in courses focusing on biotechnology in business, law medicine, biology and public health; Managers and employees in biotech and pharmaceutical companies as well as venture capitalists and financial analysts
Autoren/Hrsg.
Fachgebiete
Weitere Infos & Material
Chapter 1: INTRODUCTION
Chapter 2: MERCK: STAYING THE COURSE
Chapter 3: GENZYME: PUTTING PATIENTS FIRST
Chapter 4: MILLENNIUM PHARMACEUTICALS, INC.: CREATING AND SUSTAINING CORPORATE VALUES
Chapter 5: MAXIM PHARMACEUTICALS (A): INTERNAL AND EXTERNAL DIALOGUES
Chapter 6: DIVERSA INC.: ETHICAL ISSUES IN BIOPROSPECTING PARTNERSHIPS
Chapter 7: PIPELINE BIOTECH A/S: COMPETING REGULATORY REGIMES FOR LABORATORY ANIMAL EXPERIMENTS
Chapter 8: TGN BIOTECH: A START-UP WITH ETHICAL ROOTS
Chapter 9: INTERLEUKIN GENETICS AND ALTICOR: AN UNLIKELY PARTNERSHIP
Chapter 10: SCIONA LTD.: A PIONEER IN NUTRIGENOMICS: THE PATH TO CONSUMER ACCEPTANCE
Chapter 11: AFFYMETRIX, INC.: USING CORPORATE ETHICS ADVICE
Chapter 12: PHARMASNPS INC.: CREATING AN ETHICS ADVISORY BOARD
Chapter 13: MONSANTO COMPANY: BIO-AGRICULTURE PIONEER
Chapter 14: NOVO NORDISK: THE TRIPLE BOTTOM LINE
Chapter 15: CONCLUSION: LESSONS FOR COMPANIES AND FUTURE ISSUES
INDEX